【Polaris Pharmaceuticals-KY】Voluntary Withdrawal of BLA for Pegargiminase (ADI-PEG 20) for Malignant Pleural Mesothelioma
Polaris Pharmaceuticals announced on May 25, 2026, that it will voluntarily withdraw its BLA for Pegargiminase (ADI-PEG 20) for the treatment of malignant pleural mesothelioma with the US FDA, citing strategic development and lifecycle management.
📋 Article Processing Timeline
- 📰 Published: May 25, 2026 at 09:00
- 🔍 Collected: May 26, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: June 1, 2026 at 23:39 (159h 38m after Collected)
1. Product: Pegargiminase (ADI-PEG 20). 2. Background: The company submitted the BLA via rolling submission on Nov 16, 2023, and entered review in August 2025. 3. Reason: After evaluating development timelines, lifecycle management, and global market strategy, the company decided to withdraw to maintain flexibility for future applications. 4. Impact: This is a strategic adjustment, not a rejection by the regulator. There is no material impact on the company's financial or operational status. 5. Future: The company will continue to evaluate other indications and development paths.
FAQ
Why did the company withdraw the FDA application?
To preserve flexibility for future development based on market and lifecycle strategy.